Why is Divis Laboratories Ltd falling/rising?

Recent Price Movement and Sector Context

Divis Laboratories has been on a downward trajectory for the past six consecutive trading sessions, accumulating a loss of 9.23% during this period. The stock’s intraday low touched ₹6,000, marking a 2.3% decline on 20-Jan alone. This performance is in line with the Pharmaceuticals & Drugs sector, which itself declined by 2.15% on the same day, indicating that sector-wide pressures are contributing to the stock’s fall.

Further compounding the negative sentiment is the stock’s position relative to its moving averages. Divis Laboratories is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a bearish trend and weakening momentum. This technical weakness often discourages short-term investors and traders, adding to selling pressure.

Investor participation has also waned, with delivery volumes on 19-Jan falling by nearly 25% compared to the five-day average. This decline in trading activity suggests reduced enthusiasm among investors, which can exacerbate price declines in a falling market.

Fundamental Strengths Amidst Price Weakness

Despite the recent price decline, Divis Laboratories maintains several strong fundamental attributes. The company boasts a high return on equity (ROE) of 17.24%, reflecting efficient management and profitable use of shareholder capital. Its return on capital employed (ROCE) for the half-year stands at an impressive 20.94%, underscoring operational effectiveness.

Financial discipline is evident in the company’s negligible debt-to-equity ratio, averaging zero, which reduces financial risk and interest burden. Additionally, Divis Laboratories has reported positive results for five consecutive quarters, with quarterly net sales reaching a record ₹2,715 crore. The company’s annual dividend per share of ₹30.00 also signals confidence in cash flow generation and shareholder returns.

Institutional investors hold a significant 39.36% stake in the company, indicating confidence from sophisticated market participants who typically conduct thorough fundamental analysis. With a market capitalisation of ₹1,62,939 crore, Divis Laboratories is the second largest entity in its sector, representing over 7% of the Pharmaceuticals & Drugs industry by market value.

Valuation and Growth Concerns Weigh on Sentiment

Despite these positives, the stock’s valuation and growth profile have raised concerns among investors. Over the past five years, the company’s net sales have grown at a modest annual rate of 9.86%, while operating profit has expanded by only 5.38% annually. This relatively slow growth contrasts with the premium valuation at which the stock trades.

Divis Laboratories carries a price-to-book value ratio of 10.3, significantly higher than its peers’ historical averages. This elevated valuation implies high expectations for future growth, which the company’s recent performance has struggled to meet. Over the last year, the stock’s return was essentially flat at -0.09%, even as profits rose by 35.4%. This disparity results in a price/earnings-to-growth (PEG) ratio of 1.8, suggesting the stock may be overvalued relative to its earnings growth.

Comparative Performance and Outlook

When benchmarked against the Sensex, Divis Laboratories has underperformed in the short term. Over one week, the stock declined 6.65% compared to the Sensex’s 1.73% fall. Similarly, over one month and year-to-date periods, the stock’s losses of 7.29% and 6.08% respectively outpace the broader market’s declines. However, over a three-year horizon, the stock has delivered a robust 79.75% gain, more than double the Sensex’s 35.56% return, highlighting its long-term growth potential despite recent setbacks.

Investors should weigh the company’s strong fundamentals and sector leadership against its stretched valuation and recent price weakness. The current downtrend, coupled with subdued investor participation and sector headwinds, suggests caution in the near term.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →